Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 591.48%11.44M | 241.53%3.23M | 122.13%5.33M | 273.04%3.67M | -240.86%-786K | 118.39%1.66M | -6.68%-2.29M | 254.67%2.4M | 148.86%983K | 116.93%558K |
Net income from continuing operations | 474.84%8.36M | 1,161.03%3.66M | 2,518.89%2.36M | 224.18%1.66M | 153.62%681K | 80.83%-2.23M | 130.18%290K | 103.75%90K | 69.08%-1.34M | 67.73%-1.27M |
Operating gains losses | 42.00%284K | 98.11%-15K | -58.81%208K | --0 | -19.47%91K | -25.93%200K | 16.95%-794K | 294.53%505K | -37.54%376K | -77.22%113K |
Depreciation and amortization | 3.49%1.69M | 5.76%441K | -2.49%430K | 3.76%414K | 7.67%407K | 14.90%1.64M | 15.19%417K | 20.82%441K | 12.71%399K | 10.53%378K |
Deferred tax | ---2.67M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Other non cash items | -50.00%75K | 1,929.73%751K | -2,062.16%-726K | --197K | ---147K | --150K | --37K | --37K | ---- | ---- |
Change In working capital | 558.54%2.63M | 114.06%562K | 288.32%3.03M | -22.48%1.05M | -254.32%-2M | -1,950.00%-574K | -250.61%-4M | 111.68%779K | 17.83%1.35M | 424.00%1.3M |
-Change in receivables | -84.12%431K | 65.23%2M | 2,663.29%2.18M | -111.43%-183K | -1,948.85%-3.57M | 206.14%2.71M | 122.34%1.21M | -93.07%79K | 191.17%1.6M | -105.02%-174K |
-Change in inventory | 344.11%5.95M | 123.04%698K | 120.73%2.9M | 1,260.98%952K | 320.25%1.4M | 53.21%-2.44M | -172.25%-3.03M | 134.22%1.31M | 94.17%-82K | 84.69%-637K |
-Change in prepaid assets | -851.91%-2.99M | -3,138.03%-2.16M | -106.21%-1.2M | 979.07%464K | -165.79%-100K | -660.71%-314K | -46.62%71K | -35.20%-580K | -96.58%43K | 116.81%152K |
-Change in payables and accrued expense | 77.89%-691K | 160.63%1.51M | -86.61%-1.76M | 97.79%-24K | -130.19%-420K | -145.42%-3.13M | -234.54%-2.49M | -126.70%-941K | -138.98%-1.09M | 5.86%1.39M |
-Change in other current assets | -369.18%-1.31M | -67,100.00%-1.34M | 102.44%1K | 25.00%10K | 109.84%24K | -520.00%-279K | -300.00%-2K | -485.71%-41K | 120.00%8K | -24,500.00%-244K |
-Change in other current liabilities | ---- | ---- | ---- | -25.00%-15K | -25.00%-15K | ---- | ---- | ---- | ---12K | ---12K |
-Change in other working capital | -56.71%1.24M | -157.14%-140K | -6.37%867K | -118.15%-159K | -17.93%673K | 238.89%2.87M | -64.13%245K | 2,253.49%926K | 172.05%876K | 806.90%820K |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 591.48%11.44M | 241.53%3.23M | 122.13%5.33M | 273.04%3.67M | -240.86%-786K | 118.39%1.66M | -6.68%-2.29M | 254.67%2.4M | 148.86%983K | 116.93%558K |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 41.66%-1.24M | -29.08%-364K | 50.60%-453K | 37.42%-204K | 63.85%-214K | -20.97%-2.12M | 64.35%-282K | -274.29%-917K | 11.65%-326K | -71.59%-592K |
Net PPE purchase and sale | 41.66%-1.24M | -29.08%-364K | 50.60%-453K | 37.42%-204K | 63.85%-214K | -20.97%-2.12M | 64.35%-282K | -274.29%-917K | 11.65%-326K | -71.59%-592K |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 41.66%-1.24M | -29.08%-364K | 50.60%-453K | 37.42%-204K | 63.85%-214K | -20.97%-2.12M | 64.35%-282K | -274.29%-917K | 11.65%-326K | -71.59%-592K |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -429.50%-6.59M | -98.36%32K | -3,442.31%-3.68M | -377.02%-3.78M | -10.54%840K | -4.21%2M | 139.53%1.96M | -40.54%-104K | -141.08%-792K | 261.06%939K |
Net issuance payments of debt | -10,411.11%-6.62M | --0 | -3,048.72%-3.68M | -356.83%-3.78M | -9.09%840K | -101.53%-63K | -103.24%-43K | -126.96%-117K | -133.98%-827K | 1,284.62%924K |
Net common stock issuance | -96.99%32K | -96.80%32K | --0 | --0 | --0 | --1.06M | --1M | --13K | --35K | --15K |
Proceeds from stock option exercised by employees | --0 | ---- | ---- | ---- | ---- | --1M | ---- | ---- | ---- | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -429.50%-6.59M | -98.36%32K | -3,442.31%-3.68M | -377.02%-3.78M | -10.54%840K | -4.21%2M | 139.53%1.96M | -40.54%-104K | -141.08%-792K | 261.06%939K |
Net cash flow | ||||||||||
Beginning cash position | 80.19%3.46M | 2.63%4.17M | 10.90%2.98M | 16.76%3.3M | 80.19%3.46M | -81.87%1.92M | 0.79%4.07M | -54.47%2.69M | -55.59%2.82M | -81.87%1.92M |
Current changes in cash | 135.31%3.62M | 575.74%2.9M | -13.50%1.19M | -133.33%-315K | -117.68%-160K | 117.76%1.54M | 71.17%-610K | 173.69%1.38M | 70.20%-135K | 121.43%905K |
End cash Position | 104.72%7.08M | 104.72%7.08M | 2.63%4.17M | 10.90%2.98M | 16.76%3.3M | 80.19%3.46M | 80.19%3.46M | 0.79%4.07M | -54.47%2.69M | -55.59%2.82M |
Free cash flow | 2,309.74%10.21M | 211.80%2.87M | 229.01%4.88M | 427.09%3.46M | -2,841.18%-1M | 95.70%-462K | 12.48%-2.57M | 182.52%1.48M | 127.59%657K | 99.07%-34K |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |